Prise en charge de la neutropénie fébrile en cancérologie (notice n° 664267)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03422cam a2200313 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121193612.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Baldeyrou, Marion |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Prise en charge de la neutropénie fébrile en cancérologie |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2019.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 43 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Bien que moins fréquente et moins grave qu’en hématologie, la neutropénie fébrile (NF) reste l’un des effets secondaires les plus sévères des chimiothérapies pour cancer solide. Sa prise en charge doit être stéréotypée : i) identification précoce des signes de gravité ; ii) recherche d’un foyer infectieux clinique et prélèvement systématique d’hémocultures ; iii) administration dans l’heure qui suit le début de la prise en charge de la première dose d’antibiothérapie probabiliste ; iv) évaluation de la possibilité d’une prise en charge en ambulatoire grâce à l’aide de scores dorénavant bien validés. En ambulatoire, il est recommandé d’associer une fluoroquinolone à l’amoxicilline-acide clavulanique comme traitement probabiliste. Les traitements antibiotiques en hospitalisation dépendent de la situation clinique. Qu’ils soient hospitalisés ou traités en ambulatoire, l’état clinique des patients doit faire l’objet de réévaluation régulière afin de pouvoir adapter au plus vite le traitement antibiotique qu’ils reçoivent. Grâce à cette démarche stéréotypée, les patients se verront offrir une prise en charge en cas de NF, parfaitement sécurisée et la moins contraignante possible, le recours à l’hospitalisation n’étant pas systématique. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Although less frequent and severe than in hematological setting, febrile neutropenia (FN) is one of the most feared complication following chemotherapy for solid cancer. Its management has to be stereotyped: i) early detection of life-threatening organ dysfunction; ii) complete history and physical examination to identify infectious foci and systematic blood-cultures sample; iii) administration of the first dose of empirical antibiotherapy within the first hour after initial presentation; iv) identification of patients candidates for outpatient management. An oral fluoroquinolone plus amoxicillin/clavulanate is recommended as empirical outpatient therapy. Different types of antibiotic treatments are recommended for hospitalized patients, according to the patients’ clinical presentation. Whether they are hospitalized or not, patients’ clinical condition must be reassessed regularly in order to adapt the antimicrobial therapy if they remain febrile. Thanks to this systematic approach, management of patients with NF can be perfectly safe even for patients eligible for outpatient management. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | neutropénie fébrile |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | prise en charge |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | chimiothérapie |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cancer solide |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | solid cancer |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | febrile neutropenia |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | management |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | chemotherapy |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Le Bot, Audrey |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Limonta, Silvia |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Tattevin, Pierre |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Revest, Matthieu |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hépato-Gastro & Oncologie Digestive | 26 | N° Supp 1 | 2019-07-15 | p. 34-40 | 2115-3310 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-hepato-gastro-et-oncologie-digestive-2019-HS1-page-34?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-hepato-gastro-et-oncologie-digestive-2019-HS1-page-34?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux